ADO - ANTEOTECH LTDAnteoTech Announces First Commercial Evaluation of AnteoBind NXT21/08/2024 3:49AM AnteoTech announced that the Company has commenced an evaluation of AnteoBind NXT with Indian biotech, Vidcare Innovations (Vidcare), for inclusion in their range of blood diagnostic test products. AnteoBind NXT demonstrated by Vidcare Innovations to improve particle activation being applied to Vidcare's novel and proprietary in-home test for diagnosis of hypothyroidism. Vidcare evaluation to confirm AnteoBind NXT provides higher specificity, improved costs and ease of manufacture compared to conventional EDC chemistry. Hypothyroidism or underactive thyroid is a major health issue if left untreated - prevalent in developing countries. Vidcare Innovations initiatives are aligned with the Indian Government's 'Health for All' initiative. First Commercial Evaluation of AnteoBind NXT (Requires Adobe Acrobat Reader)
[/table][/table]
ADO Price at posting:
3.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)